.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Management of high-grade gliomas (HGG) remains one of the most significant challenges in modern oncology. Standard care involving surgery, radiation, and temozolomide often leads to severe, persistent lymphopenia. This reduction in immune cells directly correlates with poorer survival outcomes. Consequently, researchers are investigating novel therapies like NT-I7 for gliomas to restore immune function and improve patient prognosis.
NT-I7 (efineptakin alfa) is a long-acting recombinant human interleukin-7 (IL-7). This cytokine is vital for the development, survival, and homeostasis of lymphocytes. In recent clinical trials, NT-I7 demonstrated the ability to significantly increase absolute lymphocyte counts (ALC) in patients. Therefore, it serves as a critical potential adjunct to standard treatments that typically deplete these cells.
A Phase I clinical trial recently evaluated the safety and efficacy of NT-I7 in newly diagnosed HGG patients. The study determined that NT-I7 is well-tolerated, with a maximum tolerated dose (MTD) of 720 µg/kg. Furthermore, the administration of this therapy resulted in a sustained increase in lymphocyte counts for over 12 weeks. Specifically, it induced a selective expansion of CD8+ T cell clonotypes, which are essential for anti-tumor immunity.
Moreover, the study observed early elevations in CD4+ T cells and NK cells. These changes coincided with increased levels of TNF and CXCL9 cytokines, indicating active immune engagement. Interestingly, patients with MGMT promoter-unmethylated glioblastoma—a subgroup with typically poor prognosis—showed promising clinical responses. This finding suggests that NT-I7 might be particularly beneficial when combined with other immune-based therapies.
The ability of NT-I7 to maintain immune cell populations during aggressive chemoradiotherapy is revolutionary. Because lymphopenia often limits the effectiveness of immunotherapy, reversing this state is a high priority. Currently, researchers are exploring combinations of NT-I7 with checkpoint inhibitors like pembrolizumab. Additionally, further Phase II studies will clarify its impact on overall survival and progression-free survival.
NT-I7 acts as a long-acting IL-7 analog that promotes the proliferation and survival of T cells. It specifically increases absolute lymphocyte counts and expands CD8+ T cell clones to enhance the body\'s immune response against the tumor.
The therapy was generally well-tolerated. Common adverse events included injection site reactions, flu-like symptoms, and fatigue. Dose-limiting toxicities were only noted at higher doses, leading to an MTD of 720 µg/kg.
In clinical evaluations, a single administration of NT-I7 significantly increased absolute lymphocyte counts for a duration exceeding 12 weeks.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
NT-I7 (efineptakin alfa) increases absolute lymphocyte counts and expands CD8+ T cells in high-grade glioma patients, offering a new way to combat lymphopen...
5 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
